$CRL · CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Charles River Laboratories filed an 8-K disclosing its 2026 Investor Day presentation, which introduces the "Pathway to Purpose" strategic plan. The company reaffirmed FY2026 guidance with revenue and non-GAAP EPS now expected at the upper ends of prior ranges (0%–1% organic growth; $11.15–$11.45). Long-term targets through 2030 include a 5%–7% organic revenue CAGR, ~24% non-GAAP operating margin, and low-double-digit non-GAAP EPS CAGR, underpinned by over $300 million in cumulative savings from the Create the Future™ program.

Extended-hours trading shows a modest -0.23% dip to $276.70, suggesting the market is not yet pricing in the long-term targets. The regular session has not had an opportunity to react; the pre-market session will be the first real test of whether the 2030 targets and $300M savings plan resonate.

A multi-year strategic roadmap with quantified savings and margin targets gives investors a concrete framework to evaluate CRL's execution — and a benchmark to hold management accountable.

Charles River's emphasis on AI-assisted digital tools and bioanalysis expansion mirrors the CRO sector's broader pivot toward tech-enabled services. Peers like IQVIA and Thermo Fisher are similarly investing in digital platforms to capture growing biopharma R&D spend.

Forward-looking targets through 2030 exclude future acquisitions and divestitures and are explicitly not financial guidance — they are subject to significant uncertainties. Execution risk on the Pathway to Purpose strategy and Create the Future™ program is flagged as a key variable.